Abstract
Dementia and diabetes are the two major disorders that are linked at both biochemical and molecular levels, which is due to the existing similarities between pancreatic beta-cells and neuronal cells at the transcriptional and translational levels. Both diseases have similar causative genes or factors, and dementia is one of the advanced complications in about 50-52% of patients with Type 2 Diabetes Mellitus (T2DM). Further, patients with T2DM are at a higher risk of neuronal degeneration and Alzheimer’s Disease (AD). Dementia, which is most common in AD, is associated with diminished insulin receptors by nearly 80%. The impairment in insulin signaling thus leads to the development of dementia and AD. Biochemical changes in ‘tau’ protein and amyloid-- beta proteins make them critical players in the formation of plaques in patients with dementia and AD. Here, we decode various cellular and molecular mechanisms associated with the development of dementia in patients with diabetes and AD.
Keywords: Dementia, AD (alzheimer disease), T2DM (Type 2 diabetes mellitus), disorders, biochemical, pancreatic.
CNS & Neurological Disorders - Drug Targets
Title:Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
Volume: 20 Issue: 7
Author(s): Mahmood Rasool*, Arif Malik, Sulayman Waquar, Ahmad Zaheer, Muhammad Asif, Zafar Iqbal, Kalamegam Gauthaman*, Mohammad Amjad Kamal and Peter Natesan Pushparaj*
Affiliation:
- Center of Excellence in Genomic Medicine Research, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah,Saudi Arabia
- Center of Excellence in Genomic Medicine Research, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah,Saudi Arabia
- Center of Excellence in Genomic Medicine Research, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah,Saudi Arabia
Keywords: Dementia, AD (alzheimer disease), T2DM (Type 2 diabetes mellitus), disorders, biochemical, pancreatic.
Abstract: Dementia and diabetes are the two major disorders that are linked at both biochemical and molecular levels, which is due to the existing similarities between pancreatic beta-cells and neuronal cells at the transcriptional and translational levels. Both diseases have similar causative genes or factors, and dementia is one of the advanced complications in about 50-52% of patients with Type 2 Diabetes Mellitus (T2DM). Further, patients with T2DM are at a higher risk of neuronal degeneration and Alzheimer’s Disease (AD). Dementia, which is most common in AD, is associated with diminished insulin receptors by nearly 80%. The impairment in insulin signaling thus leads to the development of dementia and AD. Biochemical changes in ‘tau’ protein and amyloid-- beta proteins make them critical players in the formation of plaques in patients with dementia and AD. Here, we decode various cellular and molecular mechanisms associated with the development of dementia in patients with diabetes and AD.
Export Options
About this article
Cite this article as:
Rasool Mahmood *, Malik Arif , Waquar Sulayman , Zaheer Ahmad , Asif Muhammad , Iqbal Zafar , Gauthaman Kalamegam *, Kamal Amjad Mohammad and Pushparaj Natesan Peter *, Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease, CNS & Neurological Disorders - Drug Targets 2021; 20 (7) . https://dx.doi.org/10.2174/1871527320666210212114116
DOI https://dx.doi.org/10.2174/1871527320666210212114116 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypothalamic Control of Energy Balance
Current Drug Targets The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Renin Angiotensin System as a Regulator of Cell Volume. Implications to Myocardial Ischemia
Current Cardiology Reviews Clozapine Safety, 40 Years Later
Current Drug Safety Characteristics and Outcomes of Children with Type-I Diabetes Mellitus Hospitalized for Ketoacidosis
Current Diabetes Reviews Diabetes in Racial and Ethnic Minorities in the United States: Individualizing Approaches to Diagnosis and Management
Current Diabetes Reviews Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Anti-HCV Prevalence among Diabetic and Non-Diabetic Egyptian Children
Current Diabetes Reviews Ultra-Fast Acting Insulin Analogues
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of C1858T Polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian Children and Adolescents with Type 1 Diabetes
Current Diabetes Reviews Somatostatin and its Analogs
Current Drug Targets Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology The Impact of Oxidative Stress on Islet Transplantation and Monitoring the Graft Survival by Non-Invasive Imaging
Current Medicinal Chemistry Risks Associated with SGLT2 Inhibitors: An Overview
Current Drug Safety Activated T Lymphocytes in Type 2 Diabetes: Implications From in Vitro Studies
Current Drug Targets Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Diabetes and its Complications - Contemporary Treatment and Potential Side Effects of Drugs to Treat Diabetes
Current Drug Safety The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design Towards Newer Molecular Targets for Chronic Diabetic Complications
Current Vascular Pharmacology